

Antoni Ribas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8938043/publications.pdf>

Version: 2024-02-01

399
papers

120,657
citations

399

133
h-index

132

334
g-index

425
all docs

425
docs citations

425
times ranked

80411
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	27.0	6,976
2	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014, 515, 568-571.	27.8	5,429
3	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
4	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	12.6	4,274
5	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	27.0	3,753
6	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 707-723.	28.9	3,483
7	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 809-819.	27.0	3,288
8	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	27.0	3,128
9	IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	8.2	2,560
10	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016, 165, 35-44.	28.9	2,437
11	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2016, 375, 819-829.	27.0	2,430
12	Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. <i>Nature</i> , 2010, 464, 1067-1070.	27.8	2,292
13	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	27.0	2,240
14	Survival in BRAF V600E Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	27.0	1,955
15	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. <i>Nature</i> , 2010, 468, 973-977.	27.8	1,944
16	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	27.0	1,824
17	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. <i>Nature</i> , 2010, 467, 596-599.	27.8	1,610
18	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , The, 2014, 384, 1109-1117.	13.7	1,588

#	ARTICLE	IF	CITATIONS
19	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	12.6	1,575
20	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
21	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. <i>Nature</i> , 2012, 487, 500-504.	27.8	1,561
22	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	10.7	1,419
23	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). <i>Nature</i> , 2011, 480, 387-390.	27.8	1,298
24	Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. <i>Cell Reports</i> , 2017, 19, 1189-1201.	6.4	1,256
25	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
26	Classifying Cancers Based on T-cell Infiltration and PD-L1. <i>Cancer Research</i> , 2015, 75, 2139-2145.	0.9	1,167
27	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017, 170, 1109-1119.e10.	28.9	1,124
28	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	13.7	1,032
29	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. <i>Nature</i> , 2012, 487, 505-509.	27.8	1,029
30	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	9.4	997
31	<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. <i>New England Journal of Medicine</i> , 2012, 366, 207-215.	27.0	978
32	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	27.6	945
33	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
34	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	10.7	890
35	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	7.4	857
36	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	22.7	856

#	ARTICLE	IF	CITATIONS
37	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. <i>Cancer Discovery</i> , 2014, 4, 80-93.	9.4	836
38	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260.	10.7	832
39	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	10.7	812
40	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 143-158.	27.6	753
41	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	1.6	720
42	Hepatotoxicity with Combination of Vemurafenib and Ipilimumab. <i>New England Journal of Medicine</i> , 2013, 368, 1365-1366.	27.0	655
43	The "cancer immunogram". <i>Science</i> , 2016, 352, 658-660.	12.6	655
44	Reprogramming human T cell function and specificity with non-viral genome targeting. <i>Nature</i> , 2018, 559, 405-409.	27.8	630
45	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	1.6	627
46	Multiple early factors anticipate post-acute COVID-19 sequelae. <i>Cell</i> , 2022, 185, 881-895.e20.	28.9	605
47	Tumor Immunotherapy Directed at PD-1. <i>New England Journal of Medicine</i> , 2012, 366, 2517-2519.	27.0	597
48	Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. <i>Cancer Cell</i> , 2018, 33, 890-904.e5.	16.8	575
49	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. <i>Nature Communications</i> , 2012, 3, 724.	12.8	567
50	Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte "Associated Antigen 4 Monoclonal Antibody CP-675,206. <i>Journal of Clinical Oncology</i> , 2005, 23, 8968-8977.	1.6	563
51	Programmed Death-Ligand 1 Expression and Response to the Anti "Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	1.6	528
52	Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. <i>Cell</i> , 2015, 162, 1271-1285.	28.9	516
53	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712.	12.8	503
54	Adaptive Immune Resistance: How Cancer Protects from Immune Attack. <i>Cancer Discovery</i> , 2015, 5, 915-919.	9.4	495

#	ARTICLE	IF	CITATIONS
55	PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. <i>Cancer Research</i> , 2011, 71, 2750-2760.	0.9	488
56	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , 2018, 19, 310-322.	10.7	486
57	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> ^{V600E} melanoma. <i>Science Translational Medicine</i> , 2015, 7, 279ra41.	12.4	470
58	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	1.6	439
59	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15003.	30.5	417
60	Single-cell analysis tools for drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 204-216.	46.4	407
61	A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. <i>Nature Medicine</i> , 2011, 17, 738-743.	30.7	403
62	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3205-3211.	1.6	395
63	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 730-749.	9.4	367
64	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	1.6	360
65	Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients. <i>Science Translational Medicine</i> , 2014, 6, 238ra70.	12.4	348
66	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1767-1774.	1.6	335
67	Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11449-11454.	7.1	325
68	CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. <i>Clinical Cancer Research</i> , 2014, 20, 2424-2432.	7.0	323
69	PD-1 Blockade Expands Intratumoral Memory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 194-203.	3.4	321
70	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <i>Cell</i> , 2018, 172, 825-840.e18.	28.9	312
71	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256.	16.8	299
72	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. <i>Current Opinion in Immunology</i> , 2015, 33, 23-35.	5.5	298

#	ARTICLE	IF	CITATIONS
73	Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1075-1081.	1.6	296
74	Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 3446-3457.	7.0	294
75	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	27.8	290
76	Current Developments in Cancer Vaccines and Cellular Immunotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2415-2432.	1.6	287
77	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 47-53.	2.0	287
78	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , 2020, 183, 818-834.e13.	28.9	287
79	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	9.4	283
80	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.8	269
81	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	27.8	269
82	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. <i>Cancer Research</i> , 2014, 74, 2340-2350.	0.9	266
83	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	10.7	266
84	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 73-82.	0.9	265
85	What does PD-L1 positive or negative mean?. <i>Journal of Experimental Medicine</i> , 2016, 213, 2835-2840.	8.5	263
86	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1233-1238.	7.0	260
87	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	30.7	256
88	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. <i>Journal of Clinical Investigation</i> , 2013, 123, 1371-1381.	8.2	256
89	Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. <i>Science</i> , 2018, 359, 1037-1042.	12.6	254
90	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	7.0	253

#	ARTICLE	IF	CITATIONS
91	Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. <i>Cancer Research</i> , 2014, 74, 153-161.	0.9	249
92	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 936-940.	30.7	246
93	SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. <i>Cancer Discovery</i> , 2018, 8, 1250-1257.	9.4	244
94	Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. <i>Cancer Discovery</i> , 2014, 4, 423-433.	9.4	242
95	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 48-56.	3.2	240
96	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	4.1	236
97	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	2.8	236
98	BRAF targeted therapy changes the treatment paradigm in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 426-433.	27.6	229
99	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 954-965.	10.7	225
100	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	7.0	222
101	SnapShot: Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2017, 31, 848-848.e1.	16.8	221
102	A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four β -Fetoprotein Peptides. <i>Clinical Cancer Research</i> , 2006, 12, 2817-2825.	7.0	217
103	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
104	BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy. <i>Cancer Research</i> , 2012, 72, 3928-3937.	0.9	210
105	Releasing the Brakes on Cancer Immunotherapy. <i>New England Journal of Medicine</i> , 2015, 373, 1490-1492.	27.0	207
106	Combinatorial Treatments That Overcome PDGFR ² -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition. <i>Cancer Research</i> , 2011, 71, 5067-5074.	0.9	206
107	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 1389-1398.	10.7	206
108	Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 2457-2465.	7.0	204

#	ARTICLE	IF	CITATIONS
109	Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032. <i>Journal of Translational Medicine</i> , 2010, 8, 39.	4.4	203
110	Conserved Interferon- γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. <i>Cancer Cell</i> , 2020, 38, 500-515.e3.	16.8	203
111	Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. <i>Clinical Cancer Research</i> , 2003, 9, 998-1008.	7.0	197
112	Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. <i>PLoS ONE</i> , 2011, 6, e28973.	2.5	196
113	Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13679-13684.	7.1	196
114	<i>BRAF</i> L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 791-797.	9.4	194
115	Polymer Nanofiber-Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 3379-3383.	13.8	194
116	MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E420-9.	7.1	194
117	Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 6267-6276.	7.0	191
118	Combining Targeted Therapy With Immunotherapy in <i>BRAF</i> -Mutant Melanoma: Promise and Challenges. <i>Journal of Clinical Oncology</i> , 2014, 32, 2248-2254.	1.6	184
119	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	2.8	183
120	Marked, Homogeneous, and Early [¹⁸ F]Fluorodeoxyglucose-Positron Emission Tomography Responses to Vemurafenib in <i>BRAF</i> -Mutant Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1628-1634.	1.6	172
121	Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. <i>Cancer Discovery</i> , 2021, 11, 233-236.	9.4	169
122	Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. <i>Molecular Systems Biology</i> , 2012, 8, 589.	7.2	168
123	Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer. <i>Oncologist</i> , 2007, 12, 873-883.	3.7	160
124	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
125	CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. <i>Journal of Translational Medicine</i> , 2009, 7, 35.	4.4	157
126	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers Response. <i>Clinical Cancer Research</i> , 2019, 25, 3469-3470.	7.0	151

#	ARTICLE	IF	CITATIONS
127	The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms. <i>Clinical Cancer Research</i> , 2012, 18, 2502-2514.	7.0	145
128	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	12.0	143
129	The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations. <i>Clinical Cancer Research</i> , 2010, 16, 6040-6048.	7.0	142
130	CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans. <i>Clinical Cancer Research</i> , 2011, 17, 4101-4109.	7.0	142
131	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. <i>Cancer Discovery</i> , 2014, 4, 69-79.	9.4	141
132	Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3001-3001.	1.6	140
133	Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer. <i>PLoS ONE</i> , 2010, 5, e11726.	2.5	139
134	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	2.8	137
135	Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824. <i>Cancer Research</i> , 2009, 69, 8693-8699.	0.9	136
136	T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4883-4890.	7.0	135
137	Recurrent Tumor Cell Intrinsic and Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. <i>Cancer Discovery</i> , 2017, 7, 1248-1265.	9.4	134
138	T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein. <i>Journal of Immunology</i> , 2001, 166, 5300-5308.	0.8	131
139	Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. <i>Cancer Discovery</i> , 2013, 3, 418-429.	9.4	130
140	Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. <i>Cancer Discovery</i> , 2018, 8, 935-943.	9.4	130
141	A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma. <i>Molecular Therapy</i> , 2011, 19, 1913-1922.	8.2	129
142	T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5902-8.	7.0	129
143	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.9	126
144	Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model. <i>Cancer Research</i> , 2005, 65, 7194-7204.	0.9	121

#	ARTICLE	IF	CITATIONS
145	Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade. <i>Clinical Cancer Research</i> , 2009, 15, 390-399.	7.0	120
146	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3003-3003.	1.6	120
147	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	4.6	119
148	T cell antigen discovery via trogocytosis. <i>Nature Methods</i> , 2019, 16, 183-190.	19.0	117
149	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	6.4	114
150	Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab. <i>Seminars in Oncology</i> , 2010, 37, 450-454.	2.2	113
151	Targeted Therapies to Improve Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 4385-4391.	7.0	110
152	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 845-857.	3.4	110
153	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
154	Determinant spreading and tumor responses after peptide-based cancer immunotherapy. <i>Trends in Immunology</i> , 2003, 24, 58-61.	6.8	107
155	Ionizing Radiation Affects Human MART-1 Melanoma Antigen Processing and Presentation by Dendritic Cells. <i>Journal of Immunology</i> , 2004, 173, 2462-2469.	0.8	107
156	Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy. <i>Journal of Immunotherapy</i> , 2004, 27, 354-367.	2.4	107
157	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. <i>JCI Insight</i> , 2018, 3, .	5.0	107
158	Adenovirus MART-1-engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2008, 31, 294-309.	2.4	104
159	T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. <i>Nature Methods</i> , 2019, 16, 191-198.	19.0	103
160	Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. <i>Leukemia and Lymphoma</i> , 2018, 59, 1785-1796.	1.3	102
161	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	2.8	100
162	Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3771-3778.	1.6	99

#	ARTICLE	IF	CITATIONS
163	Targeting Oncogenic Drivers and the Immune System in Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 499-506.	1.6	98
164	Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?. <i>Clinical Cancer Research</i> , 2009, 15, 7116-7118.	7.0	97
165	Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E1408-16.	7.1	97
166	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1140-1157.	9.4	97
167	Preexisting <i>MEK1</i> Exon 3 Mutations in <i>V600E/K</i> <i>BRAF</i> Melanomas Do Not Confer Resistance to BRAF Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 414-424.	9.4	91
168	Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. <i>Molecular Cancer</i> , 2014, 13, 194.	19.2	90
169	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> <i>V600E</i> Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
170	Imaging of CTLA4 Blockade-Induced Cell Replication with ¹⁸ F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab. <i>Journal of Nuclear Medicine</i> , 2010, 51, 340-346.	5.0	89
171	Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells. <i>Nature Communications</i> , 2020, 11, 4830.	12.8	88
172	In Vivo Therapy of Hepatocellular Carcinoma with a Tumor-Specific Adenoviral Vector Expressing Interleukin-2. <i>Human Gene Therapy</i> , 1997, 8, 2173-2182.	2.7	86
173	IFN γ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. <i>Cancer Discovery</i> , 2021, 11, 2248-2265.	9.4	86
174	PAK4 inhibition improves PD-1 blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 46-58.	13.2	85
175	Precise T cell recognition programs designed by transcriptionally linking multiple receptors. <i>Science</i> , 2020, 370, 1099-1104.	12.6	85
176	Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells. <i>Journal of the American Chemical Society</i> , 2009, 131, 9695-9703.	13.7	84
177	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	2.8	84
178	Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. <i>Oncolmmunology</i> , 2014, 3, e29244.	4.6	83
179	Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. <i>Oncolmmunology</i> , 2016, 5, e1052212.	4.6	83
180	Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. <i>Journal of Translational Medicine</i> , 2011, 9, 76.	4.4	82

#	ARTICLE	IF	CITATIONS
181	5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235.	7.0	82
182	The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade. <i>Clinical Cancer Research</i> , 2014, 20, 4982-4984.	7.0	80
183	Phase 2 study of <i>RO</i> 4929097, a gamma-secretase inhibitor, in metastatic melanoma: <i>SWOG</i> 0933. <i>Cancer</i> , 2015, 121, 432-440.	4.1	80
184	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discovery</i> , 2021, 11, 2998-3007.	9.4	80
185	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	30.7	78
186	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. <i>Cancer Cell</i> , 2021, 39, 1375-1387.e6.	16.8	78
187	Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: <i>SWOG</i> S0512. <i>PLoS ONE</i> , 2012, 7, e48787.	2.5	77
188	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016, 67, 46-54.	2.8	77
189	Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to <i>JAK1</i> loss in melanoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	77
190	Targeted Therapy for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 251-262.	0.5	75
191	Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer. <i>JAMA Ophthalmology</i> , 2014, 132, 1005.	2.5	74
192	Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. <i>Nature Communications</i> , 2020, 11, 2345.	12.8	74
193	Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. <i>Journal of Translational Medicine</i> , 2008, 6, 22.	4.4	73
194	The new era of adjuvant therapies for melanoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 535-536.	27.6	73
195	New Challenges in Endpoints for Drug Development in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 336-341.	7.0	72
196	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with <i>BRAF</i> V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
197	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020, 26, 1564-1568.	30.7	71
198	Cancer Immunotherapy Using Gene-Modified Dendritic Cells. <i>Current Gene Therapy</i> , 2002, 2, 57-78.	2.0	70

#	ARTICLE	IF	CITATIONS
199	Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e283-e287.	1.6	70
200	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. <i>European Journal of Cancer</i> , 2015, 51, 2689-2697.	2.8	69
201	A Pilot Trial of the Combination of Transgenic NY-ESO-1â€œreactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. <i>Clinical Cancer Research</i> , 2019, 25, 2096-2108.	7.0	69
202	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. <i>Nature Communications</i> , 2020, 11, 660.	12.8	68
203	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
204	Intraâ€œLymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial. <i>Clinical Cancer Research</i> , 2011, 17, 2987-2996.	7.0	65
205	Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. <i>Molecular Cancer</i> , 2012, 11, 22.	19.2	65
206	Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. <i>Molecular Cancer</i> , 2014, 13, 83.	19.2	65
207	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in <i>BRAF</i> V600â€œMutated Metastatic Melanoma. <i>JAMA Oncology</i> , 2018, 4, 1382.	7.1	65
208	Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. <i>Cell Reports</i> , 2019, 28, 2728-2738.e7.	6.4	65
209	Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. <i>Journal of Translational Medicine</i> , 2011, 9, 196.	4.4	64
210	Generation of T-Cell Immunity to a Murine Melanoma Using MART-1â€œEngineered Dendritic Cells. <i>Journal of Immunotherapy</i> , 2000, 23, 59-66.	2.4	63
211	Genetically Modified Dendritic Cells for Cancer Immunotherapy. <i>Current Gene Therapy</i> , 2005, 5, 619-628.	2.0	62
212	Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1931-1943.	4.2	62
213	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015, 51, 1435-1443.	2.8	61
214	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Nonâ€œSmall Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5061-5068.	7.0	60
215	NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain. <i>Journal of Immunology</i> , 2006, 177, 8448-8455.	0.8	59
216	Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1279-1289.	4.2	59

#	ARTICLE	IF	CITATIONS
217	Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14286-14291.	7.1	59
218	Combining cancer immunotherapy and targeted therapy. Current Opinion in Immunology, 2013, 25, 291-296.	5.5	59
219	Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.. Journal of Clinical Oncology, 2014, 32, 3005-3005.	1.6	58
220	Human Dendritic Cell Maturation by Adenovirus Transduction Enhances Tumor Antigen-Specific T-Cell Responses. Journal of Immunotherapy, 2004, 27, 191-200.	2.4	57
221	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discovery, 2016, 2, 16028.	6.7	57
222	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
223	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncology, The, 2021, 22, 370-380.	10.7	57
224	Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade). Journal of Immunology, 2006, 176, 4757-4765.	0.8	56
225	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology, 2016, 28, 73-80.	5.6	56
226	Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunology Research, 2017, 5, 118-126.	3.4	56
227	Disparities in Cancer Prevention in the COVID-19 Era. Cancer Prevention Research, 2020, 13, 893-896.	1.5	54
228	Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nature Communications, 2016, 7, 12348.	12.8	52
229	Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human $\hat{I}\pm$ -fetoprotein. Molecular Immunology, 2000, 37, 943-950.	2.2	51
230	Anti-CTLA4 antibody clinical trials in melanoma. Update on Cancer Therapeutics, 2007, 2, 133-139.	0.4	51
231	Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206). Oncologist, 2008, 13, 10-15.	3.7	51
232	New drug targets in metastatic melanoma. Journal of Pathology, 2014, 232, 134-141.	4.5	50
233	Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10702-E10711.	7.1	50
234	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	12.8	50

#	ARTICLE	IF	CITATIONS
235	Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells. <i>Molecular Therapy</i> , 2013, 21, 1044-1054.	8.2	49
236	Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. <i>Molecular Cancer</i> , 2015, 14, 27.	19.2	49
237	Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. <i>BMC Cancer</i> , 2015, 15, 356.	2.6	48
238	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019, 25, 542-557.e9.	11.1	48
239	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	1.6	48
240	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020, 125, 114-120.	2.8	47
241	MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. <i>Clinical Immunology</i> , 2010, 136, 338-347.	3.2	46
242	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". <i>Journal of Translational Medicine</i> , 2008, 6, 81.	4.4	45
243	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	2.0	45
244	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018, 24, 1805-1815.	7.0	45
245	Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. <i>Cell Reports Medicine</i> , 2020, 1, 100139.	6.5	45
246	Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. <i>Cancer Discovery</i> , 2021, 11, 714-735.	9.4	45
247	Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 163-169.	0.7	44
248	ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. <i>Nature Communications</i> , 2017, 8, 241.	12.8	44
249	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9504-9504.	1.6	44
250	CD4+CD25 ^{hi} T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model. <i>Journal of Immunology</i> , 2008, 181, 1063-1070.	0.8	43
251	Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. <i>International Immunology</i> , 2009, 21, 155-165.	4.0	43
252	A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 18-24.	2.0	43

#	ARTICLE	IF	CITATIONS
253	Cardiotoxicities of novel cancer immunotherapies. <i>Heart</i> , 2021, 107, 1694-1703.	2.9	42
254	Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. <i>Journal of Translational Medicine</i> , 2009, 7, 68.	4.4	41
255	The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 368-374.	2.0	41
256	Anti-PD-1 Therapy in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 466-473.	2.2	41
257	Gauging the Long-Term Benefits of Ipilimumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1865-1866.	1.6	41
258	Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance. <i>PLoS Computational Biology</i> , 2019, 15, e1007034.	3.2	41
259	Potentiating adoptive cell therapy using synthetic IL-9 receptors. <i>Nature</i> , 2022, 607, 360-365.	27.8	41
260	Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays. <i>Clinical Cancer Research</i> , 2006, 12, 107-116.	7.0	40
261	siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide. <i>Journal of Investigative Dermatology</i> , 2011, 131, 453-460.	0.7	39
262	RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 268-282.	8.7	39
263	Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. <i>Cell Reports Medicine</i> , 2021, 2, 100449.	6.5	39
264	PET Imaging of Cancer Immunotherapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 865-868.	5.0	38
265	Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway. <i>Journal of Translational Medicine</i> , 2011, 9, 192.	4.4	38
266	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	4.2	38
267	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	7.1	38
268	Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. <i>Cancer Gene Therapy</i> , 1999, 6, 523-536.	4.6	37
269	Lentiviral Vector-mediated Autonomous Differentiation of Mouse Bone Marrow Cells into Immunologically Potent Dendritic Cell Vaccines. <i>Molecular Therapy</i> , 2007, 15, 971-980.	8.2	37
270	COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. <i>Molecular Oncology</i> , 2014, 8, 250-260.	4.6	37

#	ARTICLE	IF	CITATIONS
271	Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. <i>Journal of Translational Medicine</i> , 2012, 10, 236.	4.4	36
272	Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. <i>Journal of Controlled Release</i> , 2018, 282, 156-165.	9.9	36
273	A $\hat{2}$ -Camera Integrated with a Microfluidic Chip for Radioassays Based on Real-Time Imaging of Glycolysis in Small Cell Populations. <i>Journal of Nuclear Medicine</i> , 2011, 52, 815-821.	5.0	35
274	Melanoma dedifferentiation induced by IFN- $\hat{3}$ epigenetic remodeling in response to anti- \hat{C} PD-1 therapy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	35
275	MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. <i>Oncotarget</i> , 2017, 8, 17795-17809.	1.8	35
276	Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors. <i>Journal of Immunotherapy</i> , 2010, 33, 557-569.	2.4	34
277	A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 47-58.	2.6	34
278	Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2010, 8, 89.	4.4	33
279	Update on Immunotherapy for Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 687-694.	4.9	33
280	Gene Expression Profiling in <i>BRAF</i> -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. <i>Clinical Cancer Research</i> , 2017, 23, 5238-5245.	7.0	32
281	Genomic Features of Exceptional Response in Vemurafenib $\hat{\pm}$ Cobimetinib- \hat{C} treated Patients with <i>BRAF</i> -V600-mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246.	7.0	32
282	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 46-53.	7.0	32
283	Adjuvant Pembrolizumab versus IFN- $\hat{2}$ b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	9.4	32
284	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. <i>Clinical Cancer Research</i> , 2022, 28, 1680-1689.	7.0	32
285	HSV-sr39TK Positron Emission Tomography and Suicide Gene Elimination of Human Hematopoietic Stem Cells and Their Progeny in Humanized Mice. <i>Cancer Research</i> , 2014, 74, 5173-5183.	0.9	30
286	Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. <i>Oncotarget</i> , 2015, 6, 24823-24841.	1.8	29
287	High frequency of brain metastases after adjuvant therapy for high- \hat{C} risk melanoma. <i>Cancer Medicine</i> , 2017, 6, 2576-2585.	2.8	27
288	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	7.0	27

#	ARTICLE	IF	CITATIONS
289	Genetic Immunotherapy for Cancer. <i>Oncologist</i> , 2000, 5, 87-98.	3.7	26
290	Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. <i>Cancer Gene Therapy</i> , 2005, 12, 516-527.	4.6	25
291	Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma. <i>PLoS ONE</i> , 2010, 5, e12711.	2.5	24
292	Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure. , 2015, 3, .		23
293	Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10013-10013.	1.6	23
294	Preparation of peptideâ€‘MHC and T-cell receptor dextramers by biotinylated dextran doping. <i>BioTechniques</i> , 2017, 62, 123-130.	1.8	22
295	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	13.2	22
296	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 562-567.	5.0	22
297	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	1.6	22
298	Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells. <i>Journal of Immunology</i> , 2004, 172, 4762-4769.	0.8	21
299	The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T-cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer Therapy. <i>Journal of Immunotherapy</i> , 2010, 33, 759-768.	2.4	21
300	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. <i>Melanoma Research</i> , 2017, 27, 585-590.	1.2	21
301	Endocrinopathies with use of cancer immunotherapies. <i>Clinical Endocrinology</i> , 2018, 88, 327-332.	2.4	20
302	Impact of depth of response on survival in patients treated with cobimetinibâ€‘vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. <i>British Journal of Cancer</i> , 2019, 121, 522-528.	6.4	20
303	Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. <i>Cell Discovery</i> , 2019, 5, 62.	6.7	20
304	At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 261-264.	3.4	20
305	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021, 11, 1336-1344.	9.4	20
306	IL-32 ³ potentiates tumor immunity in melanoma. <i>JCI Insight</i> , 2020, 5, .	5.0	20

#	ARTICLE	IF	CITATIONS
307	Anti-HER2/neu IgG3 ⁺ (IL-2) and anti-HER2/neu IgG3 ⁺ (GM-CSF) promote HER2/neu processing and presentation by dendritic cells: Implications in immunotherapy and vaccination strategies. <i>Molecular Immunology</i> , 2006, 43, 667-676.	2.2	19
308	Immunosensitization with a Bcl-2 small molecule inhibitor. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 699-708.	4.2	19
309	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation ⁺ positive melanoma. <i>British Journal of Cancer</i> , 2018, 118, 777-784.	6.4	19
310	Adverse events 2.0 ⁺ Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	2.8	19
311	Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. <i>Cancer Discovery</i> , 2021, 11, 1881-1885.	9.4	19
312	Immunotherapy of hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 123-133.	3.1	18
313	Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function. <i>Cancer Immunology Research</i> , 2014, 2, 459-468.	3.4	18
314	Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. <i>Clinics in Dermatology</i> , 2009, 27, 603-613.	1.6	17
315	Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene ⁺ modified dendritic cell vaccines. <i>Cancer Gene Therapy</i> , 2002, 9, 875-883.	4.6	16
316	Therapeutic Cancer Vaccines. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 819-831.	1.5	16
317	A phase 1 ⁺ study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. <i>Cancer</i> , 2010, 116, 3683-3691.	4.1	16
318	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
319	Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma. <i>American Journal of Ophthalmology</i> , 2007, 143, 958-969.e2.	3.3	15
320	Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab. <i>PLoS ONE</i> , 2013, 8, e76829.	2.5	15
321	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	15
322	Central Role of the Antigen-Presentation and Interferon- γ Pathways in Resistance to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2022, 6, 85-102.	4.5	15
323	Impact of <i>MET</i> expression on outcome in <i>BRAF</i> ^{V600E/K} advanced melanoma. <i>Histopathology</i> , 2013, 63, 351-361.	2.9	14
324	Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. <i>Journal of Immunology</i> , 2022, 209, 696-709.	0.8	14

#	ARTICLE	IF	CITATIONS
325	PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. , 2013, 1, 14.		13
326	CRAF R391W is a melanoma driver oncogene. Scientific Reports, 2016, 6, 27454.	3.3	13
327	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
328	First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.. Journal of Clinical Oncology, 2017, 35, 2508-2508.	1.6	13
329	BRAF-targeted therapy and immune responses to melanoma. OncoImmunology, 2013, 2, e24462.	4.6	12
330	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
331	A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication. PLoS ONE, 2018, 13, e0191634.	2.5	12
332	Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity. Journal of Clinical Investigation, 2022, 132, .	8.2	12
333	Interleukin 32 expression in human melanoma. Journal of Translational Medicine, 2019, 17, 113.	4.4	11
334	Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. Cancer Discovery, 2020, 10, 1645-1653.	9.4	11
335	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).. Journal of Clinical Oncology, 2014, 32, 3000-3000.	1.6	11
336	Tumours switch to resist. Nature, 2012, 490, 347-348.	27.8	10
337	Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, The, 2015, 16, 15-17.	10.7	10
338	Anti-PD-1 antibody treatment for melanoma. Lancet Oncology, The, 2018, 19, e219.	10.7	10
339	Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.	7.0	10
340	How Did We Get a COVID-19 Vaccine in Less Than 1 Year?. Clinical Cancer Research, 2021, 27, 2136-2138.	7.0	10
341	Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discovery, 2021, 11, 2158-2167.	9.4	10
342	IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. , 2021, 9, e002232.		10

#	ARTICLE	IF	CITATIONS
343	Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival. <i>Cancer Immunology Research</i> , 2014, 2, 981-987.	3.4	9
344	Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation ⁺ positive metastatic melanoma treated with vemurafenib \pm cobimetinib. <i>European Journal of Cancer</i> , 2019, 116, 45-55.	2.8	9
345	IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. <i>Clinical Cancer Research</i> , 2019, 25, 1000-1011.	7.0	9
346	Multiplexed imaging reveals an IFN- γ -driven inflammatory state in nivolumab-associated gastritis. <i>Cell Reports Medicine</i> , 2021, 2, 100419.	6.5	9
347	STARBOARD: encorafenib ⁺ binimetinib ⁺ pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanoma. <i>Future Oncology</i> , 2022, 18, 2041-2051.	2.4	9
348	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). , 2022, 10, e004226.		9
349	Clinical Trials With Tumor Antigen Genetically Modified Dendritic Cells. <i>Seminars in Oncology</i> , 2005, 32, 556-562.	2.2	8
350	Excluding T Cells: Is β -Catenin the Full Story?. <i>Cancer Cell</i> , 2015, 27, 749-750.	16.8	8
351	Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib \pm cobimetinib: a pooled analysis of four clinical trials. <i>Journal of Translational Medicine</i> , 2020, 18, 294.	4.4	8
352	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. <i>Clinical Cancer Research</i> , 2021, 27, 4500-4510.	7.0	8
353	Antigen Presentation Keeps Trending in Immunotherapy Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3239-3241.	7.0	7
354	Gene editing: Towards the third generation of adoptive T-cell transfer therapies. <i>Immuno-Oncology Technology</i> , 2019, 1, 19-26.	0.3	7
355	Impact of COVID-19 Pandemic on Cancer Research. <i>Cancer Cell</i> , 2020, 38, 591-593.	16.8	7
356	Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report. <i>Immunotherapy</i> , 2021, 13, 283-288.	2.0	7
357	Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9009-9009.	1.6	7
358	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600 ⁺ mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.. <i>Journal of Clinical Oncology</i> , 2020, 38, 57-57.	1.6	7
359	Malignant Lymphoproliferative Diseases in HIV-Seropositive Patients: A study of 40 cases at a single institution in Spain. <i>Acta Oncologica</i> , 1995, 34, 75-82.	1.8	6
360	How important is hepatitis C virus (HCV)-infection in persons with acute leukemia?. <i>Leukemia Research</i> , 1997, 21, 785-788.	0.8	6

#	ARTICLE	IF	CITATIONS
361	Reply to K.S. Wilson et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2836-2837.	1.6	6
362	Association of programmed death ligand 1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 516-522.	3.3	6
363	Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3106-TPS3106.	1.6	6
364	Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. <i>Contemporary Clinical Trials</i> , 2004, 25, 400-407.	1.9	5
365	Interferon Alfa in the Postsurgical Management of High-Risk Melanoma: Is It Worth It?. <i>Journal of Clinical Oncology</i> , 2009, 27, 2896-2897.	1.6	5
366	T Cells as the Future of Cancer Therapy. <i>Cancer Discovery</i> , 2021, 11, 798-800.	9.4	5
367	Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2528-2528.	1.6	5
368	Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 675-678.	3.8	5
369	Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy. , 2022, 10, e004190.		5
370	Broad antitumor protection by dendritic cells administered to CD8± knock out mice. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 663-671.	4.2	4
371	Immunoediting the cancer genome – a new approach for personalized cancer therapy?. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 297-298.	3.3	4
372	Triple therapy for BRAFV600-mutated melanoma. <i>Lancet, The</i> , 2020, 395, 1814-1815.	13.7	4
373	Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. <i>PLoS ONE</i> , 2021, 16, e0252597.	2.5	4
374	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. <i>European Journal of Cancer</i> , 2022, 160, 1-11.	2.8	4
375	Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling. <i>Future Oncology</i> , 2010, 6, 1671-1673.	2.4	3
376	Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 288-289.	3.3	3
377	Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. <i>Journal of Immunotherapy</i> , 2018, 41, 248-259.	2.4	3
378	Trying for a BRAF Slam Dunk. <i>Cancer Discovery</i> , 2020, 10, 640-642.	9.4	3

#	ARTICLE	IF	CITATIONS
379	Novel Insights/Translational Implication from the Emerging Biology of Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 3-9.	0.9	3
380	Immune rejection in a humanized model of murine prostate cancer. <i>Anticancer Research</i> , 2010, 30, 409-14.	1.1	3
381	Frequent Dose Delays and Growth Factor Requirements with the Sequential Doxorubicin-CMF Schedule. <i>Acta OncolÃ³gica</i> , 1997, 36, 701-704.	1.8	2
382	Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (mut) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8518-8518.	1.6	2
383	Kinetic Inference Resolves Epigenetic Mechanism of Drug Resistance in Melanoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
384	Reply to Perris, Borghese, and Magro. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 983-985.	3.3	1
385	HMGB1 Mediates Endogenous TLR2 Activation And Brain Tumor Regression.. <i>FASEB Journal</i> , 2008, 22, 515-515.	0.5	1
386	KIR Genetics Modifies Susceptibility to Inflammatory Disorder by Reprogramming Human Natural Killer Cell Function. <i>Blood</i> , 2012, 120, 3282-3282.	1.4	1
387	424. Myd88/TLR Signaling Is Required for Immunotherapy-Mediated Glioblastoma Regression. <i>Molecular Therapy</i> , 2006, 13, S163.	8.2	0
388	Editorial Comment on: Vaccine Therapy in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 1342-1343.	1.9	0
389	Cancer Research in the 21st Century. <i>Annals of Surgery</i> , 2016, 264, 555-565.	4.2	0
390	P863â€¦KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma. , 2020, , .		0
391	65. Accurate neoantigen prediction depends on mutation position relative to patient-specific MHC anchor locations. <i>Cancer Genetics</i> , 2020, 244, 24-25.	0.4	0
392	Abstract 3006: Melanoma cell lines derived from patient derived xenografts (PDX) can contain murine chromosomes resultant from cell fusions. , 2021, , .		0
393	Leadership Focus on Advancing Cancer Research and Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1178-1180.	5.0	0
394	Generation of Dendritic Cells after One-Hit Lentiviral Transduction of Hematopoietic Precursor Cells: Proof of Concept for the Human and Mouse Systems.. <i>Blood</i> , 2004, 104, 3448-3448.	1.4	0
395	Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. , 2009, , 575-590.		0
396	Introduction: Cancer vaccinesâ€™ mechanisms and a clinical overview. , 2011, , 1-8.		0

#	ARTICLE	IF	CITATIONS
397	Effect of anti-CTLA-4 antibody treatment on T-cell repertoire evolution in treated cancer patients.. Journal of Clinical Oncology, 2013, 31, 3020-3020.	1.6	0
398	A Pre-Clinical Model Of Hematopoietic Stem Cell Based Immunotherapy For Cancer Utilizing The NY-ESO-1 T-Cell Receptor and sr39TK PET Reporter / Suicide Gene. Blood, 2013, 122, 2020-2020.	1.4	0
399	426â€¦MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma. , 2020, , .		0